Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma.

In Phase II (active phase) CAT-354 inhibited AHR ( Figure 6D ) as measured by PC 30 (theoretical dose of intravenous histamine required to increase baseline lung resistance by 30%) but this did not reach statistical significance ( Figure 6E ).

also in 111,027 other papers